COCH Form 4 reports purchase transactions

Kantor Susan reported open-market purchase transactions in a Form 4 filing for COCH.

Rhea-AI Filing Summary

Kantor Susan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 249,990 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 57,690 shares.

Insider Trade Summary

Net Buyer: 249,990 shares

Net Buy 5 txns

Insider Kantor Susan

Role Director

Bought 249,990 shs ($38K)

Type	Security	Shares	Price	Value
Purchase	Warrant (right to buy)	57,690	$0.00	$0.00
Purchase	Warrant (right to buy)	96,150	$0.00	$0.00
Purchase	Class A Common Stock	96,150	$0.40	$38K
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Warrant (right to buy) — 153,840 contracts (Direct); Class A Common Stock — 174,037 shares (Direct); Stock Option (right to buy) — 125,000 contracts (Direct)

Footnotes (4)

1. F1. Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
2. F2. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
3. F3. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
4. F4. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Envoy Medical (COCH) report for Susan Kantor?

Envoy Medical reported that director Susan Kantor bought 96,150 shares of Class A Common Stock at $0.40 per share. The same Form 4 also shows her acquiring two warrant positions and holding previously granted stock options linked to the company’s shares.

How many Envoy Medical (COCH) shares does Susan Kantor own after the Form 4?

After the reported transaction, Susan Kantor directly owns 174,037 shares of Envoy Medical Class A Common Stock. This total reflects the purchase of 96,150 shares on February 12, 2026, combined with her previously held shares disclosed in the filing.

What warrants did Susan Kantor acquire in the Envoy Medical (COCH) filing?

Susan Kantor acquired two warrant positions: 57,690 Series A‑1 Warrants and 96,150 Series A‑2 Warrants, each exercisable for Class A Common Stock at $0.40 per share. Both warrant acquisitions were reported as open‑market or private purchases on February 12, 2026.

When do Susan Kantor’s Envoy Medical (COCH) Series A-1 and A-2 Warrants expire?

The Series A‑1 Warrants expire on the earlier of two years from their initial exercise date or 30 days after Envoy Medical announces submission of a Premarket Approval Application to the FDA. Series A‑2 Warrants expire five years from initial exercise or 30 days after FDA approval announcement.

What stock option awards for Envoy Medical (COCH) are reported for Susan Kantor?

The filing lists two stock option grants for 62,500 shares each of Class A Common Stock. One option vests 15,625 shares on October 15, 2024, with the remaining 46,875 shares vesting pro rata on the 15th of each month for 36 months.

How was the purchase price reported for Susan Kantor’s Envoy Medical (COCH) warrants?

The warrants carry an exercise price of $0.40 per underlying share, but the Form 4 shows a purchase price of $0.00 per warrant. The transactions are coded as open‑market or private purchases under transaction code “P.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:47 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kantor Susan

(Last) (First) (Middle)

C/O ENVOY MEDICAL, INC.

4875 WHITE BEAR PARKWAY

(Street)

WHITE BEAR LAKE MN 55110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Envoy Medical, Inc. [ COCH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/12/2026		P		96,150	A	$0.4	174,037	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.4							(1)	10/15/2033	Class A Common Stock	62,500		62,500	D
Stock Option (right to buy)	$0.813							05/01/2026	12/03/2035	Class A Common Stock	62,500		62,500	D
Warrant (right to buy)	$0.4	02/12/2026		P		57,690		(2)	(3)	Class A Common Stock	57,690	$0	57,690	D
Warrant (right to buy)	$0.4	02/12/2026		P		96,150		(2)	(4)	Class A Common Stock	96,150	$0	96,150	D

Explanation of Responses:

1. Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

2. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

3. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

4. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

	/s/ Andrew Nick as Attorney-in-Fact for Susan J. Kantor pursuant to Power of Attorney filed herewith.	02/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.